Lisi Zeng

1.2k total citations
31 papers, 865 citations indexed

About

Lisi Zeng is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Lisi Zeng has authored 31 papers receiving a total of 865 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Cancer Research and 6 papers in Surgery. Recurrent topics in Lisi Zeng's work include Cancer-related molecular mechanisms research (9 papers), MicroRNA in disease regulation (8 papers) and Circular RNAs in diseases (7 papers). Lisi Zeng is often cited by papers focused on Cancer-related molecular mechanisms research (9 papers), MicroRNA in disease regulation (8 papers) and Circular RNAs in diseases (7 papers). Lisi Zeng collaborates with scholars based in China and United States. Lisi Zeng's co-authors include Shuzhong Cui, Xianzi Yang, Quanxing Liao, Qingjun He, Tiantian Cheng, Ziying Lei, Zhen Tang, Jun Chi, Hong Zhang and Hongsheng Tang and has published in prestigious journals such as PLoS ONE, ACS Applied Materials & Interfaces and Annals of Oncology.

In The Last Decade

Lisi Zeng

29 papers receiving 852 citations

Peers

Countries citing papers authored by Lisi Zeng

Since Specialization

Citations

This map shows the geographic impact of Lisi Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisi Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisi Zeng more than expected).

Fields of papers citing papers by Lisi Zeng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisi Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisi Zeng. The network helps show where Lisi Zeng may publish in the future.

Co-authorship network of co-authors of Lisi Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Lisi Zeng. A scholar is included among the top collaborators of Lisi Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisi Zeng. Lisi Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Membrane-based natural gas dehydration: Techno-economic analysis of membrane process designs with different potential application scenarios 2025 ·Separation and Purification Technology ·(unknown), Lisi Zeng, Qing Li, Zhongde Dai, Zhe Zhang, Shouliang Yi	1
2	PD-1/PD-L1 inhibitor treatment associated with cardiotoxicity regulated by macrophage polarization and SOCS3/JAK/STAT3 signaling pathway 2025 ·Central European Journal of Immunology ·(unknown), Ge Wang, Lisi Zeng, Jiamin Lin, (unknown), Wei Xu, (unknown), (unknown)	1
3	Paclitaxel hyperthermia suppresses gastric cancer migration through MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin axis 2024 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Chang Liu, Zheng Li, (unknown), (unknown), Yun‐Xin Lu, Quanxing Liao, (unknown), Hongsheng Tang, Xianzi Yang, Lisi Zeng	1
4	Hsa_circ_0051908 Promotes Hepatocellular Carcinoma Progression by Regulating the Epithelial–Mesenchymal Transition Process 2024 ·Analytical Cellular Pathology ·(unknown), (unknown), Shuzhong Cui, Quanxing Liao, Lisi Zeng, Yinuo Tu	1
5	667P Furmonertinib 160mg as first-line treatment for metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases 2024 ·Annals of Oncology ·Yuanyuan Zhang, Lisi Zeng, Ning Yang, (unknown), Ying Xiong, Z. Wang, (unknown), Li Liu, Caicun Zhou, F. Zeng	0
6	Progress and outlook on severe slugging mitigation techniques for offshore hydrocarbon production: A systematic review 2024 ·Geoenergy Science and Engineering ·(unknown), Lisi Zeng, Zhe Zhang, (unknown), (unknown), (unknown)	0
7	Increased expression of LINC00323 correlates with tumor progression and poor prognosis of gastric cancer 2023 ·Cancer Biomarkers ·(unknown), Jinjie Li, Qin Lu, Chao Yang, Lei Ma, Chuan Jin, Shuzhong Cui, (unknown), Lisi Zeng, Xianzi Yang	2
8	Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy 2022 ·Frontiers in Oncology ·Lisi Zeng, Xubo Huang, Yun Tian, Jinxia Huang, Huiyan Liu, (unknown), Kaihua Liu, Yang Shao, Jiali Luo, Hongsheng Tang, Quanxing Liao, Ziying Lei, (unknown), Qianghua Xia, Tianpei Guan, Jin Li, Shuzhong Cui	2
9	Construction of a competing endogenous RNA network and identification of potential regulatory axes in gastric cancer chemoresistance 2022 ·Pathology - Research and Practice ·Xianzi Yang, Lei Ma, (unknown), (unknown), (unknown), Chuan Jin, Wei Liu, Qin Lu, Lisi Zeng, Shuzhong Cui	4
10	Multifunctional Non-Coding RNAs Mediate Latent Infection and Recurrence of Herpes Simplex Viruses 2021 ·Infection and Drug Resistance ·Ying Zhang, Lisi Zeng, Juan Wang, Wen-Qi Cai, (unknown), (unknown), Xiaochun Peng, Zhaowu Ma, Ying Xiang, Shuzhong Cui, Hong-Wu Xin	5
11	MicroRNA-124-3p inhibited progression of nasopharyngeal carcinoma by interaction with PCDH8 and the inactivation of PI3K/AKT/mTOR pathway 2021 ·Journal of Cancer ·(unknown), Quanxing Liao, (unknown), Chang Liu, Yan Ding, Xuefeng Liu, Lisi Zeng, Tianpei Guan, Yawei Yuan	8
12	Rab1A promotes cancer metastasis and radioresistance through activating GSK-3β/Wnt/β-catenin signaling in nasopharyngeal carcinoma 2020 ·Aging ·Xianzi Yang, Ximin Chen, Lisi Zeng, Jin Deng, Lei Ma, Chuan Jin, Ren Wang, (unknown), Yue‐Feng Wen, Xiaoliang Wu, Hui‐Yun Wang, Shuzhong Cui	13
13	The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells 2020 ·Frontiers in Oncology ·Wen-Qi Cai, Lisi Zeng, Lifeng Wang, Yingying Wang, Jun-Ting Cheng, Ying Zhang, (unknown), Yang Zhou, (unknown), Xianwang Wang, Xiaochun Peng, Ying Xiang, Zhaowu Ma, Shuzhong Cui, Hong-Wu Xin	127
14	Cx43 Inhibition Attenuates Sepsis-Induced Intestinal Injury via Downregulating ROS Transfer and the Activation of the JNK1/Sirt1/FoxO3a Signaling Pathway 2019 ·Mediators of Inflammation ·Zhaowei Zou, Bin Liu, Lisi Zeng, Xianzi Yang, (unknown), Cheng Wu, Huijuan Zhu, Yi Gao, Dongdong Yuan, Jinlong Yu	47
15	Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway 2018 ·Cellular Physiology and Biochemistry ·Lisi Zeng, Quanxing Liao, Zhaowei Zou, Yue‐Feng Wen, Jingshu Wang, Chang Liu, Qingjun He, (unknown), Judeng Zeng, Hongsheng Tang, (unknown), Ziying Lei, Zhen Tang, Xianzi Yang, Shuzhong Cui	49
16	Predictive Value of LINC01133 for Unfavorable Prognosis was Impacted by Alcohol in Esophageal Squamous Cell Carcinoma 2018 ·Cellular Physiology and Biochemistry ·Xianzi Yang, Qingjun He, Tiantian Cheng, Jun Chi, Ziying Lei, Zhen Tang, Quanxing Liao, Hong Zhang, Lisi Zeng, Shuzhong Cui	20
17	Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy 2018 ·PLoS ONE ·Yue‐Feng Wen, Tiantian Cheng, (unknown), Wenjin Huang, (unknown), (unknown), Xiaodan Lin, Lisi Zeng	27
18	RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma 2018 ·Cancer Letters ·Yingying Liang, Xubin Deng, Lisi Zeng, (unknown), (unknown), Bin Wang, (unknown), Yawei Yuan	13
19	MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer 2016 ·Oncology Letters ·(unknown), Wei Yi, (unknown), Rui‐Hua Xu, Lisi Zeng, Xiaoran Long, (unknown), (unknown), Yibin Kang, Hui‐Yun Wang	15
20	miR-601 is a prognostic marker and suppresses cell growth and invasion by targeting PTP4A1 in breast cancer 2016 ·Biomedicine & Pharmacotherapy ·(unknown), Wei Yi, Xuan Wei, Mei‐Yin Zhang, Rui‐Hua Xu, Lisi Zeng, Zhijie Huang, Jingsong Chen	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact